Clinical Trials
8 trialsNCT04222972 2026-03-05
AcceleRET-Lung
Hoffmann-La Roche
Phase 3 Terminated
NCT04198766 2025-12-18
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Inhibrx Biosciences, Inc
Phase 1/2 Active not recruiting
NCT05107674 2025-09-09
A Study of NX-1607 in Adults With Advanced Malignancies
Nurix Therapeutics, Inc.
Phase 1 Recruiting
NCT05704985 2025-05-29
Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors
DEKA Biosciences
Phase 1 Active not recruiting
NCT03693612 2024-08-28
GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors
GlaxoSmithKline
Phase 1/2 Completed
NCT02051751 2020-12-08
A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer
Novartis
Phase 1 Completed
NCT00603941 2020-09-16
A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel
Daiichi Sankyo
Phase 1/2 Terminated
NCT00581971 2013-04-25
RAD0201
University of Alabama at Birmingham
Phase 1/2 Completed